Design Therapeutics 주식 (NASDAQ: DSGN)

에 대한 최신 뉴스 Design Therapeutics (NASDAQ:DSGN) 주식

Design Therapeutics

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Design Therapeutics Inc

Citigroup analyst Jenny Ping downgrades National Grid (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGG#NYSE">NGG</a>) from Buy to Neutral.

News

Downgrades

Analyst Ratings

Citigroup Downgrades National Grid to Neutral

Biotech

Large Cap

Health Care

General

The European Commission Has Approved Astrazeneca's Calquence (Acalabrutinib) In Combination With Bendamustine And Rituximab For Adult Patients With Previously Untreated Mantle Cell Lymphoma Who Are Not Eligible For Autologous Stem Cell Transplant

Guidance

Vishay Precision Group Sees Q2 Sales $70.000M-$76.000M vs $75.73M Est

Earnings

Earnings Misses

Vishay Precision Group Q1 Adj. EPS $0.04 Misses $0.07 Estimate, Sales $71.74M Miss $73.04M Estimate

Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares dropped 9.19% in pre-market trading on Tuesday, despite the data analytics company raising its revenue forecast on strong demand for artificial intelligence products.
What Happened: Wedbush Securities analyst Dan Ives defended the company&#8217;s stock <a href="https://www.youtube.com/watch?v=M4ei8oBx2rY">on</a> CNBC, calling Palantir &#8220;the Messi of AI&#8221; and predicting a trillion-dollar market cap within three years.
&#8220;They are leading when it comes to AI revolution,&#8221; Ives said. &#8220;If you look at the bears, they hate it at 30, despise it at 50, absolutely say it&#8217;s expensive at 100, 125.&#8221;
Palantir &#8220;is a core AI Revolution gem to own over the coming years,&#8221; Ives wrote on X. 
The company reported <a href="https://www.benzinga.com/news/earnings/25/05/45208000/palantir-q1-earnings-revenue-beat-eps-in-line-customer-count-up-39-company-raises-guidance-citing-surging-and-ferocious-growth">first quarter revenue of $883.86 million</a>, beating analyst estimates of $862.83 million, with earnings of 13 cents per share meeting expectations. U.S. commercial revenue surged 71% year-over-year while the customer count grew 39%.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Great to be on <a href="https://twitter.com/CNBCOvertime?ref_src=twsrc%5Etfw">@CNBCOvertime</a> with <a href="https://twitter.com/MorganLBrennan?ref_src=twsrc%5Etfw">@MorganLBrennan</a> and <a href="https://twitter.com/jonfortt?ref_src=twsrc%5Etfw">@jonfortt</a> discussing Palantir's robust results/guidance and my view this is a core AI Revolution gem to own over the coming years. Great bull/bear debate with Brent Thill &#x1f525;&#x1f3c6;&#x1f402;&#x1f4fa;&#x1f37f;&#x1f447; <a href="https://twitter.com/CNBC?ref_src=twsrc%5Etfw">@CNBC</a> <a href="https://t.co/HYQklSdyLn">https://t.co/HYQklSdyLn</a> <a href="https://t.co/fuqPAd9O4y">pic.twitter.com/fuqPAd9O4y</a>
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1919513417192267999?ref_src=twsrc%5Etfw">May 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Jefferies analyst Brent Thill, maintaining an underperform rating, acknowledged the strong fundamentals but questioned the sustainability of Palantir&#8217;s valuation at 65 times revenue.
&#8220;There&#8217;s not a single software stock that we&#8217;ve ever covered that trades at this multiple and sustained it,&#8221; Thill noted, pointing to historically lower multiples at companies like Snowflake Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>).
See Also: <a href="https://www.benzinga.com/markets/equities/25/05/45213125/bill-ackman-says-inflation-has-largely-been-wrung-out-pushes-for-temporary-pause-on-china-tariffs-to-shield-us-businesses">Bill Ackman Says Inflation Has &#8216;Largely Been Wrung Out,&#8217; Pushes For Temporary Pause On China Tariffs To Shield US Businesses</a>
Why It matters: Ives countered that valuation-focused investors &#8220;missed every transformational tech stock last 20 years,&#8221; adding that institutional investors have been &#8220;way wrong&#8221; while retail investors recognized the company&#8217;s potential.
Fundstrat&#8216;s Mark Newton supported the bullish view on X, noting the &#8220;post-close weakness has not violated uptrend&#8221; and that PLTR &#8220;remains attractive on weakness.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24PLTR&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PLTR</a> dropped 9% after hours despite raising Rev. Forecast on strong demand for its AI products Post-close weakness has not violated uptrend from 4/21 lows &amp; this remains attractive on weakness ~114. Daily charts show this to have successfully held Feb peaks on its first… <a href="https://t.co/JQYR1PJIjX">pic.twitter.com/JQYR1PJIjX</a>
&mdash; Mark Newton CMT (@MarkNewtonCMT) <a href="https://twitter.com/MarkNewtonCMT/status/1919515293694456263?ref_src=twsrc%5Etfw">May 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
CEO Alex Karp cited a &#8220;tectonic shift&#8221; in adoption, raising full-year revenue growth guidance to 36% and U.S. commercial revenue growth to 68%, <a href="https://www.benzinga.com/news/earnings/25/05/45208000/palantir-q1-earnings-revenue-beat-eps-in-line-customer-count-up-39-company-raises-guidance-citing-surging-and-ferocious-growth">describing the growth</a> as &#8220;surging and ferocious.&#8221;
Price Action: Palantir stock closed at $123.77 on Monday, down 0.41%. In pre-market trading on Tuesday, the stock dropped 9.19% to $112.40. Year-to-date, it&#8217;s up 63.65%, and 390.96% over the past year, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45212767/bitcoin-ethereum-flat-dogecoin-dips-even-as-trump-calls-crypto-popular-analyst-says-btc-build-up-good-predicts-eth-uptrend-after-fed-meet">Bitcoin, Ethereum Flat, Dogecoin Dips Even As Trump Calls Crypto &#8216;Popular:&#8217; Analyst Says BTC Build-up Good, Predicts ETH Uptrend After Fed Meet</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Markets

PLTR

SNOW

PLTR Stock Falls 9.19% In Premarket Trading, But This Analyst Remains Bullish, Predicts $1 Trillion Valuation In 3 Years

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) raises FY2025 Adj EPS guidance from $12.70-$13.00 to $12.75-$13.05 vs $12.86 analyst estimate. Raises FY2025 sales outlook from $3.03 billion-$3.11 billion to $3.11 billion-$3.17 billion vs $3.08 billion estimate.

Waters Raises FY2025 Adj EPS Guidance from $12.70-$13.00 to $12.75-$13.05 vs $12.86 Est; Raises FY2025 Sales Guidance from $3.03B-$3.11B to $3.11B-$3.17B vs $3.08B Est

Leerink Partners analyst David Risinger downgrades Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Outperform to Market Perform and lowers the price target from $550 to $503.

Price Target

VRTX

Leerink Partners Downgrades Vertex Pharmaceuticals to Market Perform, Lowers Price Target to $503

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) may be in a corrective phase, but that hasn't deterred derivatives traders from amping up bullish bets on the meme coin.
What happened: More than 72% of all Binance traders with open DOGE positions were long as of this writing, <a href="https://www.coinglass.com/TopTrader/Binance">according </a>to Coinglass, suggesting hopes of a short-term price spike.
The percentage of traders bullish on Dogecoin has steadily increased from 68.2% to the current value over the last three days. Interestingly, DOGE's price retreated nearly 9% during this period.
Furthermore, over 75% of Binance&#8217;s top traders, those possessing a higher level of expertise compared to retail investors, were positioned long on DOGE as of this writing.
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/25/05/45213365/maxine-waters-to-obstruct-cryptocurrency-hearing-plans-shadow-hearing-instead">Maxine Waters Plans Walkout From Crypto Hearing, Will Host &#8216;Shadow Hearing&#8217; Opposing Trump Family Ventures: Report</a>
Meanwhile, the crucial Moving Average Convergence Divergence indicator, which compares two exponential moving averages of an asset's price, flashed a "Sell" signal for DOGE, <a href="https://in.tradingview.com/symbols/DOGEUSD/technicals/">according</a> to TradingView.
Additionally, the Bull Bear Power indicator, which measures the strength of buyers and sellers, was "Neutral."
Why It Matters: These findings coincided with Dogecoin's pullback on Monday, joining a <a href="https://www.benzinga.com/25/05/45212767/bitcoin-ethereum-flat-dogecoin-dips-even-as-trump-calls-crypto-popular-analyst-says-btc-build-up-good-predicts-eth-uptrend-after-fed-meet">broader risk-off trend</a> ahead of the Federal Reserve&#8217;s policy meeting.
Large transactions valued at over $100,000 spiked 41% in the last 24 hours, while the daily active address count rose nearly 35%, <a href="https://app.intotheblock.com/">according</a> to IntoTheBlock.
Price Action:&nbsp; At the time of writing, DOGE was exchanging hands at $0.1675, down 3.95% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Over the week, the meme coin has dropped nearly 7%.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45214067/two-dormant-bitcoin-whales-move-325-million-after-a-decade-whats-going-on">Two Dormant Bitcoin Whales Move $325 Million After A Decade: What&#8217;s Going On?</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

Dogecoin Sees Spike In Bullish Long Bets Despite A 7% Weekly Drop: What's Next?

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) is looking for Q2 Adj EPS of $2.88-$2.98 vs $2.93 analyst estimate. sees sales of $743.955 million-$758.126 million vs $740.35 million analyst estimate.

Waters Sees Q2 Adj EPS $2.88-$2.98 vs $2.93 Est; Sees Sales $743.955M-$758.126M vs $740.35M Est

Waters Assimilates Multi-Angle Light Scattering Detectors With Empower Software For Improved Biologics Quality Control

On Monday, Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) co-founder Bill Gates spoke about the disruption in international climate cooperation in the wake of President Donald Trump's campaign.
What Happened: Speaking at Temasek Holdings' Ecosperity Week conference in Singapore, Gates said these disruptions are unlikely to last long, <a href="https://www.bloomberg.com/news/articles/2025-05-05/bill-gates-says-lack-of-climate-cooperation-is-unlikely-to-last">reported</a> Bloomberg.
"There's a lot of commitment to this cause in the United States," Gates said, referring to the clean energy transition. 
Earlier in January, on the inauguration for his second term, <a href="https://www.benzinga.com/25/01/43087966/trump-signs-orders-to-take-us-out-of-paris-climate-agreement-calls-the-deal-one-sided-and-unfair">Trump signed an executive order</a> saying, "I'm immediately withdrawing from the unfair, one-sided Paris Climate Accords." In 2017, Trump withdrew from the global climate pact, which former President Joe Biden later reversed.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/25/05/45213068/mark-zuckerberg-overtakes-jeff-bezos-to-become-worlds-second-richest-person-as-meta-stock-soars" target="_blank" rel="noreferrer noopener">Mark Zuckerberg Overtakes Jeff Bezos To Become World's Second-Richest Person As Meta Stock Soars</a>
"This current trend, where there's a little less cooperation going on, I don't think that's a permanent thing," Gates said, who appeared at the conference in his role as the founder of Breakthrough Energy, the report noted.
Why It's Important: Breakthrough Energy is a climate-tech investment firm backed by Gates, Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder Jeff Bezos and Alibaba Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) founder Jack Ma. It was established in 2015.
Last year, the firm raised $839 million in its third flagship round, which prioritized advancing climate technology and backing startups focusing on reducing emissions.
In March 2025, Breakthrough Energy announced significant operational cutbacks in an internal memo sent to staff, <a href="https://www.nytimes.com/2025/03/12/climate/bill-gates-breakthrough-energy-cuts.html">reported</a> the New York Times.
In 2021, the Bill &amp; Melinda Gates Foundation announced a $315 million package to help smallholder farmers adapt to the growing threats posed by climate change.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/45090992/mark-zuckerberg-warns-of-serious-disadvantage-as-chinas-data-center-blitz-could-let-deepseek-leapfrog-us-ai-labs" target="_blank" rel="noreferrer noopener">Mark Zuckerberg Warns Of ‘Serious Disadvantage' As China's Data-Center Blitz Could Let DeepSeek Leapfrog US AI Labs</a></li>
</ul>
Image Via Shutterstock

Tech

Media

AMZN

BABA

MSFT

Bill Gates Says Trump's Climate Rollbacks May Have Slowed Progress, But Microsoft Co-Founder Doesn't Think 'That's a Permanent Thing' As America's Commitment To Clean Energy Remains Strong

On Monday, May 5th, U.S. markets closed lower, ending their winning streaks, as markets reacted to Trump&#8217;s tariff on foreign films. Energy stocks lagged, Berkshire Hathaway stumbled after Buffett&#8217;s exit news, and Netflix, Amazon, and Paramount saw losses. Investors are now focused on the upcoming Fed decision amid rising inflation concerns and profit risks.
According to economic data, the ISM services PMI climbed to 51.6 in April, up from March&#8217;s nine-month low of 50.8, beating market expectations of 50.6.
Most S&amp;P 500 sectors fell, led by energy, consumer discretionary, and tech, while consumer staples edged higher.
The Dow Jones Industrial Average was down 0.24% at 41,218.83, the S&amp;P 500 declined 0.64% to 5,650.38, and the Nasdaq slid 0.74% to 17,844.24.
Related: <a target="_blank" href="https://www.benzinga.com/25/05/45214594/hollywood-tariff-push-sparked-by-trump-jon-voight-meeting-where-actor-proposed-levies-in-certain-limited-circumst" rel="noreferrer noopener">Hollywood Tariff Push Sparked By Trump-Jon Voight Meeting Where Actor Proposed Levies In &#8216;Certain Limited Circumstances:&#8217; Report</a>
Asia Markets Today
<ul>
<li>Japan&#8217;s market closed for the Greenery Day holiday.</li>
<li>On Tuesday, Australia&#8217;s S&amp;P/ASX 200 declined 0.08%, ending the session at 8,151.40, led by losses in the Healthcare, Consumer Staples, and Financials sectors.</li>
<li>India&#8217;s Nifty 50 was down 0.28% at 24,391.85, and Nifty 500 fell 1.03% to 24,391.85.</li>
<li>China&#8217;s Shanghai Composite gained 1.13% to 3,316.11, and Shanghai Shenzhen CSI 300 was up 1.01% to 3,808.54.</li>
<li>Hong Kong&#8217;s Hang Seng closed the session 0.70% higher at 22,662.71.</li>
</ul>
Eurozone at 05:45 AM ET
<ul>
<li>The European STOXX 50 index was down 0.90%.</li>
<li>Germany&#8217;s DAX index declined 1.22%.</li>
<li>France&#8217;s CAC 40 slid 0.70%.</li>
<li>The U.K.&#8217;s FTSE 100 index traded lower by 0.18%.</li>
</ul>
Commodities at 05:45 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 2.89% at $58.78/bbl, and Brent was up 2.86% at $61.95/bbl.</li>
<li>Oil rebounded after six declines, lifted by bargain hunting, China&#8217;s return, and technical factors, despite lingering concerns over rising OPEC+ supply and global demand.</li>
<li>Natural Gas gained 1.97% to $3.621.</li>
<li>Gold was trading higher by 2.06% at $3,390.89, Silver was up 2.47% to $33.275, and Copper rose 0.04% to $4.7013.</li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were down 0.70%, S&amp;P 500 futures declined 0.81%, and Nasdaq 100 futures fell 1.12%.
Forex at 05:45 AM ET
<ul>
<li>The U.S. Dollar Index fell 0.02% to 99.97, USD/JPY was down 0.26% to 143.31, and USD/AUD gained 0.36% to 1.5515.</li>
<li>The U.S. dollar slipped as investors grew cautious over Trump&#8217;s trade policies and awaited the Fed decision.</li>
</ul>
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Slips, Gold Nears $3,400 Again - Global Markets Today While US Slept

OPAD

Offerpad Partners With Auction.com For Real Estate Services

Offerings

FCUV

Focus Universal Announced Securities Purchase Agreement With Alumni Capital For Sale Of 1M Common Stock Shares

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, "Cyclacel" or the "Company"))) today announced that it entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; "FITTERS"), an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, "Waste-To-Resource" services and real estate development and construction.
Pursuant to the Exchange Agreement, all of the ordinary shares of FITTERS' subsidiary, Fitters Sdn. Bhd., a Malaysia-based private limited company ("Fitters Sub") shall be exchanged for common stock, par value $0.001, of Cyclacel (the "Purchaser Stock"), and Fitters Sub shall be continuing as a wholly-owned subsidiary of Cyclacel (the "Transaction"). As part of the Transaction, Cyclacel shall issue an amount of Purchaser Stock equal to 19.99% percent, which percentage may be subject to adjustment, of the issued and outstanding shares of Purchaser Stock as of the closing date to FITTERS. At the closing, it is expected that Cyclacel stockholders will own approximately 80.01% of the combined company.

CYCC

CYCCP

Cyclacel Pharmaceuticals Enters Exchange Agreement To Make FITTERS' Subsidiary, Fitters Sdn. Bhd., Its Wholly-Owned subsidiary

Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 31.43 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $8.05 million which missed the analyst consensus estimate of $8.50 million by 5.25 percent. This is a 33.63 percent increase over sales of $6.03 million the same period last year.

Earnings Beats

SQNS

Sequans Communications Q1 Adj. EPS $(0.24) Beats $(0.26) Estimate, Sales $8.05M Miss $8.50M Estimate

Compass Point analyst Joe Flynn downgrades MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) from Neutral to Sell and lowers the price target from $25 to $9.5.

MARA

Compass Point Downgrades MARA Holdings to Sell, Lowers Price Target to $9.5

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) reported quarterly earnings of $2.25 per share which beat the analyst consensus estimate of $2.22 by 1.35 percent. This is a 1.81 percent increase over earnings of $2.21 per share from the same period last year. The company reported quarterly sales of $661.71 million which beat the analyst consensus estimate of $654.76 million by 1.06 percent. This is a 3.90 percent increase over sales of $636.84 million the same period last year.

Waters Q1 Adj. EPS $2.25 Beats $2.22 Estimate, Sales $661.71M Beat $654.76M Estimate

Tutor Perini Subsidiary Fisk Electric Bags Electrical Services Contract For The New West Tower At Cook Children's Medical Center In Texas

Ingredion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>) raises FY2025 Adj EPS guidance from $10.75-$11.55 to $10.90-$11.60 vs $11.03 analyst estimate..

INGR

Ingredion Raises FY2025 Adj EPS Guidance From $10.75-$11.55 To $10.90-$11.60 vs $11.03 Est

Press Releases

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Design Therapeutics to Participate in Leerink's Global Healthcare Conference

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Management

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

Comments

Design Therapeutics

뉴스

에 대한 최신 뉴스 Design Therapeutics (NASDAQ:DSGN) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌